Compositions and methods for treatment of skin infections

Abstract

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

1 .- 84 . (canceled) 
     
     
         85 . A pharmaceutical composition comprising: a unit dose of
 at least about 15 weight % of a keratolytic agent, wherein said weight % of said keratolytic agent is based on a total weight % of said composition,   a molecule comprising an oxo group and an acidic group, ester thereof, salt thereof, or any combination thereof, and   a halogen containing moiety.   
     
     
         86 . The composition of  claim 85 , wherein said keratolytic agent is selected from the group consisting of salicylic acid, pyruvic acid, chloroacetic acid, trichloroacetic acid, menthol, acetic acid, ascorbic acid, pantothenic acid, lactic acid, a salt of any of the above, and any combination thereof 
     
     
         87 . The composition of  claim 86 , wherein said keratolytic agent is salicylic acid, ester thereof, salt thereof, or any combination thereof 
     
     
         88 . The composition of  claim 87 , comprising at least about 25 weight % of salicylic acid, ester thereof, salt thereof, or any combination thereof, wherein said weight % of salicylic acid is based on said total weight % of said composition. 
     
     
         89 . The composition of  claim 85 , comprising about 15 weight % of said molecule comprising an oxo group and an acidic group, ester thereof, salt thereof, or any combination thereof. 
     
     
         90 . The composition of  claim 89 , wherein said molecule comprising an oxo group and an acidic group, ester thereof, salt thereof, or any combination thereof, comprises a pyruvate group. 
     
     
         91 . The composition of  claim 90 , wherein said molecule comprising an oxo group and an acidic group, ester thereof, salt thereof, or any combination thereof, is ethyl pyruvate. 
     
     
         92 . The composition of  claim 85 , wherein said halogen containing moiety comprises iodine. 
     
     
         93 . The composition of  claim 92 , wherein said halogen containing moiety is polyvinylpyrrolidone-iodine. 
     
     
         94 . The composition of  claim 93 , comprising a weight % of polyvinylpyrrolidone-iodine from about 0.1% to about 1%, wherein said weight % of polyvinylpyrrolidone-iodine is based on said total weight % of said composition. 
     
     
         95 . A pharmaceutical composition, comprising:
 a weight % of salicylic acid, ester thereof, salt thereof, or any combination thereof, from about 25% to about 30%, wherein said weight % of salicylic acid is based on a total weight % of said composition,   a weight % of ethyl pyruvate, ester thereof, salt thereof, or any combination thereof, from about 10% to about 20%, wherein said weight % of ethyl pyruvate is based on a total weight % of said composition, and   a weight % of polyvinylpyrrolidone-iodine from about 0.1% to about 1%, wherein said weight % of polyvinylpyrrolidone-iodine is based on a total weight % of said composition.   
     
     
         96 . A method for treatment of a skin infection comprising administering to a subject in need thereof a therapeutically-effective amount of the composition of  claim 85 . 
     
     
         97 . A method for treatment of a wart comprising administering to a subject in need thereof a therapeutically-effective amount of a composition comprising:
 a weight % of salicylic acid, ester thereof, salt thereof, or any combination thereof, from about 25% to about 30%, wherein said weight % of salicylic acid is based on a total weight % of said composition,   a weight % of ethyl pyruvate, ester thereof, salt thereof, or any combination thereof, from about 10% to about 20%, wherein said weight % of ethyl pyruvate is based on a total weight % of said composition, and   a weight % of polyvinylpyrrolidone-iodine from about 0.1% to about 1%, wherein said weight % of polyvinylpyrrolidone-iodine is based on a total weight % of said composition.   
     
     
         98 . A method of making a pharmaceutical composition, comprising combining:
 a weight % of salicylic acid, ester thereof, salt thereof, or any combination thereof, from about 25% to about 30%, wherein said weight % of salicylic acid is based on a total weight % of said composition,   a molecule comprising an oxo group and an acidic group, ester thereof, salt thereof, or any combination thereof, and   a halogen containing moiety.